Shape 21 Experience

    SARS-CoV-2 Antibody Assays​

    An important step in the pursuit to understand immunity​

    Our SARS-CoV-2 Total and IgG antibody assays* provide a semi-quantitative and/or qualitative result. Quantitative measurements of SARS-CoV-2 antibodies help clinicians assess the level of an individual‘s immune response. This numerical value will enable detection of the level of antibodies in a patient’s blood sample. Clinicians will have a baseline and be better equipped to assess changes during the course of an individual’s immune response to the SARS-CoV-2 virus.​

    Antibody assays from Siemens Healthineers are well-positioned to aid vaccine development efforts.​

    We selected the receptor-binding domain (RBD) of the S1 spike antigen to detect neutralizing antibodies that block the virus entry into the cells. This selection is aligned with the multiple vaccines in development that target or include the SARS-CoV-2 S1 RBD, with the goal to elicit neutralizing (and therefore likely protective) antibodies in vaccinated subjects.1 The spike protein and particularly the RBD are the most common target of vaccine designs.​

    Hear from Siemens Healthineers VP of Research & Development for Immunoassays​.​

    Jim Freeman discusses how design matters for SARS-CoV-2 antibody assays, the selection of the S1 RBD antigen, and how this strategy is aligned with vaccines in development.​